News and Info

Welcome to the News and Information section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed of the latest news and activities of the organization. The information below includes press releases, announcements, media advisories, and links to news articles.

We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.


Latest News

August 17, 2026

The Summer 2026 advocacy blog Considering Clinical Trials is now available

August 17, 2026

Attention radiation oncologists and trainees: Travel funds are available for the Fall 2026 Group Meeting (apply now)

August 17, 2026

Attention CRAs: Travel funds are available for the Fall 2026 Group Meeting (apply now)

August 17, 2026

Attention APPs: Travel funds are available for the Fall 2026 Group Meeting (apply now)

August 3, 2026

The July 2026 News from ECOG-ACRIN blog is now available

July 23, 2026

Press Release: Proactive support to quit tobacco use during cancer treatment doubles quit rates in a nationwide trial

July 15, 2026

Press Release: ECOG-ACRIN ENDURANCE trial findings published in the New England Journal of Medicine provide the first randomized evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

July 9, 2026

Podcast: ASCO Post includes updated STAMP (EA6174) Merkel cell carcinoma data in its ASCO26 highlights, applauding cooperative groups for their ability to study rare cancers

June 29, 2026

The June 2026 News from ECOG-ACRIN blog is now available

June 10, 2026

Press Release: Elsa Anagnostou, Jordan Berlin, and Olisaemeka Ogbue receive ECOG-ACRIN 2026 scientific leadership and mentorship awards

June 4, 2026

A new exploratory analysis from STAMP (EA6174) on aggressive Merkel cell cancer draws attention at ASCO 2026

June 2, 2026

EA5142, an ALCHEMIST trial, adds to the knowledge base about optimal timing of adjuvant immunotherapy in non-small cell lung cancer

June 2, 2026

WATCH: Dr. Jamie Chaft discusses the results of ALCHEMIST EA5142, a randomized phase 3 study of nivolumab after surgery and adjuvant chemotherapy in non-small cell lung cancer

June 1, 2026

JAMA publishes ALCHEMIST EA5142 results: Nivolumab does not further reduce the risk of recurrence in patients with resected non-small cell lung cancer

May 28, 2026

The May 2026 News from ECOG-ACRIN blog is now available

May 21, 2026

Press Release: Guide to ECOG-ACRIN cancer research at ASCO 2026

May 19, 2026

Press Release: TAILORx and RxPONDER trials shift to a discovery platform for analyzing breast cancer recurrence using advanced tumor profiling and AI

May 15, 2026

The Spring 2026 advocacy blog Considering Clinical Trials is now available

April 27, 2026

The April 2026 News from ECOG-ACRIN blog is now available

April 8, 2026

ECOG-ACRIN vice chair Dr. Al Benson discusses the evolving role of first-line immunotherapy for advanced anal cancer, referencing the InterAACT-2 and EA2176 trials

 
ECOG-ACRIN Cancer Research Group